Sat, Oct 24, 2026
[Archive]
Volume 34, Issue 4 (July & August 2026)
J Adv Med Biomed Res 2026, 34(4): 347-356 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zarvandi M, Rajabi A, Esmaeil Mosharrafi F, Seprhrikia S. Efficacy of an Herbal Formulation (Taryaqe Vabaei) in Alleviating Symptoms of Upper Respiratory Tract Infections: A Randomized Double-Blind, Placebo-Controlled Clinical Trial. J Adv Med Biomed Res 2026; 34 (4) :347-356
URL: http://journal.zums.ac.ir/article-1-7730-en.html
URL: http://journal.zums.ac.ir/article-1-7730-en.html
1- Department of Traditional Persian Medicine, Golestan University of Medical Sciences, Gorgan, Iran
2- Department of Bistatistitics and Epidemiology, School of Health, Golestan University of Medical Siences
3- Department of Traditional Persian Medicine, Golestan University of Medical Sciences, Gorgan, Iran.(
4- Neyshabur University of Medical Sciences, Neyshabur, Iran ,Dr.sepehrikia@yahoo.com
2- Department of Bistatistitics and Epidemiology, School of Health, Golestan University of Medical Siences
3- Department of Traditional Persian Medicine, Golestan University of Medical Sciences, Gorgan, Iran.(
4- Neyshabur University of Medical Sciences, Neyshabur, Iran ,
Abstract: (767 Views)
Background & Objective: Upper respiratory tract infections (URTIs) represent a significant category of infections affecting the nose, throat, sinuses, and airways. This randomized, double-blind, placebo-controlled clinical trial investigates the efficacy of Taryaqe Vabaei, a traditional herbal formulation consisting of Aloe barbadensis, Commiphora myrrh, and Crocus sativus, in alleviating Upper Respiratory tract infections (URTIs) symptoms.
Materials & Methods: Sixty-six participants aged 25–60 years old with mild URTI symptoms were randomized into two groups. The intervention group received 500 mg of Taryaqe Vabaei twice daily for 14 days, while the control group received a placebo. Symptom severity was the primary outcome. For normally distributed data, independent and paired t-tests were used; for non-normally distributed data, the Mann-Whitney U and Wilcoxon signed-rank tests were applied. Categorical variables were analyzed using the chi-square test (SPSS v.26, significance at P<0.05).
Results: The intervention group showed significantly faster recovery times for body pain (0.85±1.23 vs. 4.36±1.82 days, p<0.001), sore throat (p<0.001), runny nose (p<0.001), cough (p<0.001), sneezing (p<0.001), fever (p<0.001), and confusion (0.71±1.43 vs. 0.06±0.36 days, p=0.01). Symptom severity decreased by 40% after one week in the intervention group, with significant improvements in overall symptom scores compared to placebo.
Conclusion: Although Taryaqe Vabaei showed promising results in reducing URTI symptoms, larger, longer-term studies are required to confirm its efficacy, explore safety profiles, and assess potential interactions with conventional treatments. These findings highlight the potential of Taryaqe Vabaei as an effective complementary therapy for managing URTIs.
Materials & Methods: Sixty-six participants aged 25–60 years old with mild URTI symptoms were randomized into two groups. The intervention group received 500 mg of Taryaqe Vabaei twice daily for 14 days, while the control group received a placebo. Symptom severity was the primary outcome. For normally distributed data, independent and paired t-tests were used; for non-normally distributed data, the Mann-Whitney U and Wilcoxon signed-rank tests were applied. Categorical variables were analyzed using the chi-square test (SPSS v.26, significance at P<0.05).
Results: The intervention group showed significantly faster recovery times for body pain (0.85±1.23 vs. 4.36±1.82 days, p<0.001), sore throat (p<0.001), runny nose (p<0.001), cough (p<0.001), sneezing (p<0.001), fever (p<0.001), and confusion (0.71±1.43 vs. 0.06±0.36 days, p=0.01). Symptom severity decreased by 40% after one week in the intervention group, with significant improvements in overall symptom scores compared to placebo.
Conclusion: Although Taryaqe Vabaei showed promising results in reducing URTI symptoms, larger, longer-term studies are required to confirm its efficacy, explore safety profiles, and assess potential interactions with conventional treatments. These findings highlight the potential of Taryaqe Vabaei as an effective complementary therapy for managing URTIs.
Keywords: Aloe barbadensis, Commiphora myrrh, Crocus sativus, Persian Medicine, Complementary Medicine, Respiratory Tract Infections.medicine
Type of Study: Clinical Trials |
Subject:
Clinical Medicine
Received: 2026/04/16 | Accepted: 2026/06/22 | Published: 2026/08/4
Received: 2026/04/16 | Accepted: 2026/06/22 | Published: 2026/08/4
References
1. Kiseleva I, Ksenafontov A. COVID-19 shuts doors to flu but keeps them open to rhinoviruses. Biology (Basel). 2021;10(8). [DOI:10.3390/biology10080733] [PMID] [PMCID]
2. Bechini A, Salvati C, Bonito B, Del Riccio M, Stancanelli E, Bruschi M, et al. Costs and healthcare utilisation due to respiratory syncytial virus disease in paediatric patients in Italy: A systematic review. Pub Health. 2024;227:103-11. [DOI:10.1016/j.puhe.2023.11.039] [PMID]
3. Wang DY, Eccles R, Bell J, Chua AH, Salvi S, Schellack N, et al. Management of acute upper respiratory tract infection: the role of early intervention. Expert Rev Respir Med. 2021;15(12):1517-23. [DOI:10.1080/17476348.2021.1988569] [PMID]
4. Momtazmanesh S, Moghaddam SS, Ghamari S-H, Rad EM, Rezaei N, Shobeiri P, et al. Global burden of Clinical Medicine. 2 chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. eClinical Medicine.2023;59: 101936
5. Mobarki AM, Al-Subaie AA, Machajy MYA, Maeid AHA, Fagihi EAA, Tayash AINK, et al. Comprehensive clinical perspectives on upper respiratory tract infections: A multidisciplinary focus on the common cold. Saudi J Med Pub Health. 2024;1(2):665-82. [DOI:10.64483/20251214]
6. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014;2014(4):Cd008965. [DOI:10.1590/1516-3180.20141324T2] [PMID] [PMCID]
7. Leung MW, O'Donoghue M, Suen LK-P. Personal and household hygiene measures for preventing upper respiratory tract infections among children: a cross-sectional survey of parental knowledge, attitudes, and practices. Int J Environ Res Public Health. 2022;20(1):229. [DOI:10.3390/ijerph20010229] [PMID] [PMCID]
8. Anheyer D, Cramer H, Lauche R, Saha FJ, Dobos G. Herbal medicine in children with respiratory tract infection: systematic review and meta-analysis. Acad Pediatr. 2018;18(1):8-19. [DOI:10.1016/j.acap.2017.06.006] [PMID]
9. Pranskuniene Z, Balciunaite R, Simaitiene Z, Bernatoniene J. Herbal medicine uses for respiratory system disorders and possible trends in new herbal medicinal recipes during COVID-19 in pasvalys district, Lithuania. Int J Environ Res Public Health. 2022;19(15). [DOI:10.3390/ijerph19158905] [PMID] [PMCID]
10. Pergolizzi JV, LeQuang JA, Magnusson P, Varrassi G. Traditional, complementary and integrative medicine approaches to COVID-19: a narrative review. OBM Integr Complement Med. 2021;6(3):1-19. [DOI:10.21926/obm.icm.2103021]
11. Aghdam HA, Khosravi R. Herbal analgesics in pediatric surgery: from traditional evidence to scientific validation. Plant Biotechnol Persa. 2025;7(4). [DOI:10.61882/pbp.7.4.1]
12. Zarvandi M, Sepehrikia S. Is there evidence for the use of an herbal" Taryaqe Vabaii" for conditions similar to COVID-19? J Curr Oncol Med Sci. 2022;2(4):353-65.
13. Boussarsar M, Ennouri E, Habbachi N, Bouguezzi N, Meddeb K, Gallas S, et al. Epidemiology and burden of Severe Acute Respiratory Infections (SARI) in the aftermath of COVID-19 pandemic: A prospective sentinel surveillance study in a Tunisian Medical ICU, 2022/2023. PLoS One. 2023;18(12):e0294960. [DOI:10.1371/journal.pone.0294960] [PMID] [PMCID]
14. Kianmehr M, Mahdizadeh F, Khazdair MR. The effects of Crocus sativus L. (Saffron) and its ingredients on dietary intakes in cardiovascular disease in Iranian population: A systematic review and meta-analysis. Front Nutr. 2022;9:890532. [DOI:10.3389/fnut.2022.890532] [PMID] [PMCID]
15. Anwar N, Ahmed NZ, Fathima AF, Khan AA. Analytical review of Tiryāq-i-Wabāī-A Unani panacea for the control of COVID-19. J Herb Med. 2023;39:100653. [DOI:10.1016/j.hermed.2023.100653] [PMID] [PMCID]
16. Aleem M, Khan MI, Danish M, Usmani QI, Ahmad A. Unani perspective on COVID-19 and the possible role of Tiryaq Wabai in its management: A Review. J Drug Deliv Ther. 2021;11(5). [DOI:10.22270/jddt.v11i5.5001]
17. Banu Z, Saidaiah P, Khan U, Geetha A, Khan S, Khan AA. Leveraging nature's pharmacy: A comprehensive review of traditional medicinal and aromatic plants against COVID-19. Ann Phytomed. 2024;13(1):37-55. [DOI:10.54085/ap.2024.13.1.4]
18. Ansari MY. Pharmacognostical studies on Gumma (Leucas cephalotes Spreng.). Rajiv Gandhi University of Health Sciences (India); 2011.
19. Huang Z, Pan X, Zhou J, Leung WT, Li C, Wang L. Chinese herbal medicine for acute upper respiratory tract infections and reproductive safety: A systematic review. Biosci Trends. 2019;13(2):117-29. [DOI:10.5582/bst.2018.01298] [PMID]
20. John LJ, Shantakumari N. Herbal medicines use during pregnancy: A review from the Middle East. Oman Med J. 2015;30(4):229-36. [DOI:10.5001/omj.2015.48] [PMID] [PMCID]
21. Itrat M, Nasir F, Akhtar Y, Ahmad I. Pharmacological treatment of upper respiratory tract infections in Unani medicine: An evidence-based review. Altern Ther Health Med. 2023;29(7):252-61.
22. Kosari M, Noureddini M, Khamechi SP, Najafi A, Ghaderi A, Sehat M, et al. The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID‐19: A clinical trial. Phytother Res. 2021;35(7):4000-6. [DOI:10.1002/ptr.7116] [PMID] [PMCID]
23. Garcia S. Pandemics and traditional plant-based remedies. A historical-botanical review in the Era of COVID19. Front Plant Sci. 2020;11:571042. [DOI:10.3389/fpls.2020.571042] [PMID] [PMCID]
24. Husaini AM, Jan KN, Wani GA. Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management. Heliyon. 2021;7(5):e07068. [DOI:10.1016/j.heliyon.2021.e07068] [PMID]
25. Hajimonfarednejad M, Ostovar M, Hasheminasab FS, Shariati MA, Thiruvengadam M, Raee MJ, et al. Medicinal plants for viral respiratory diseases: A systematic review on persian medicine. Evid Based Complement Alternat Med. 2023;2023:1928310. [DOI:10.1155/2023/1928310] [PMID] [PMCID]
26. Mammari N, Albert Q, Devocelle M, Kenda M, Kočevar Glavač N, Sollner Dolenc M, et al. Natural products for the prevention and treatment of common cold and viral respiratory infections. Pharmaceuticals (Basel). 2023;16(5). [DOI:10.3390/ph16050662] [PMID] [PMCID]
27. Wcw W, A L, At L, Kt L, Cym L, Pc L, et al. Effectiveness of a Chinese herbal medicine preparation in the treatment of cough in uncomplicated upper respiratory tract infection: a randomised double-blinded placebo-control trial. Cough. 2006;2(1):5. [DOI:10.1186/1745-9974-2-5] [PMID] [PMCID]
28. Chutia A, Saikia P, Hasan M, Das A, Siyum A. Antioxidant and anti-inflammatory potential of Aloe vera: A comprehensive review. Int J Sci Res Eng Manage. 2024;08:1-15. [DOI:10.55041/IJSREM37075]
29. Alyafei N. Can myrrh combat COVID-19? Iberoam J Med. 2020;2(3):223-9. [DOI:10.53986/ibjm.2020.0039]
30. Sánchez M, González-Burgos E, Iglesias I, Gómez-Serranillos MP. Pharmacological update properties of Aloe Vera and its major active constituents. Molecules. 2020;25(6). [DOI:10.3390/molecules25061324] [PMID] [PMCID]
31. Heng HC, Zulfakar MH, Ng PY. Pharmaceutical applications of Aloe vera. Indo J Pharm. 2018;29(3). [DOI:10.14499/indonesianjpharm29iss3pp101]
32. Bhattacharjee MK, Alenezi T. Antibiotic in myrrh from Commiphora molmol preferentially kills nongrowing bacteria. Future Sci OA. 2020;6(4):Fso458. [DOI:10.2144/fsoa-2019-0121] [PMID] [PMCID]
33. Mentis AA, Dalamaga M, Lu C, Polissiou MG. Saffron for "toning down" COVID-19-related cytokine storm: Hype or hope? A mini-review of current evidence. Metabol Open. 2021;11:100111. [DOI:10.1016/j.metop.2021.100111] [PMID] [PMCID]
34. Fong HH. Integration of herbal medicine into modern medical practices: issues and prospects. Integr Cancer Ther. 2002;1(3):287-93 [DOI:10.1177/153473540200100313] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Journal of Advances in Medical and Biomedical Research by Zanjan University of Medical Sciences is licensed under CC BY-NC 4.0
